Все аудиоразборы

Аудиоразбор · Другие заболевания глаз

Лечение ВМД. Добавки

Визлея, витамины и другие средства при возрастной макулярной дегенерации: разбираем исследования, составы и место добавок в лечении.

Автор аудиоразбора

Иван Исаков, врач-офтальмолог

Литература, использованная при подготовке аудиоразбора

  1. Bausch Health. Визлея: листок-вкладыш БАД к пище, P1KZ01 [Internet]. 2023 [cited 2026 Oct 18]. Available from: https://www.bausch.kz/upload/Vislea_KZ_leaflet_P1KZ01_02-2023.pdf
  2. Малахова АИ. Применение витаминно-минерального комплекса у пациента с промежуточной стадией возрастной макулярной дегенерации и онкологической патологией в анамнезе. Клинические случаи в офтальмологии. 2024;2(6):4-7. doi:10.25276/2949-4494-2024-2-4-7.
  3. National Institute for Health and Care Excellence. Age-related macular degeneration: recommendations. NICE guideline NG82 [Internet]. London: NICE; 2018 [cited 2026 Oct 18]. Available from: https://www.nice.org.uk/guidance/ng82/chapter/recommendations
  4. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436. doi:10.1001/archopht.119.10.1417. Erratum in: Arch Ophthalmol. 2008;126(9):1251. doi:10.1001/archopht.126.9.1251.
  5. Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Kurinij N, et al. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120(8):1604-11.e4. doi:10.1016/j.ophtha.2013.01.021. Erratum in: Ophthalmology. 2016;123(12):2634. doi:10.1016/j.ophtha.2016.10.026.
  6. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023;9:CD000254. doi:10.1002/14651858.cd000254.pub5.
  7. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. doi:10.1001/jama.2013.4997. Erratum in: JAMA. 2013;310(2):208. doi:10.1001/jama.2013.6403.
  8. Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132(2):142-149. doi:10.1001/jamaophthalmol.2013.7376.
  9. Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140(7):692-698. doi:10.1001/jamaophthalmol.2022.1640.
  10. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000253. doi:10.1002/14651858.cd000253.pub4.
  11. Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study. Ophthalmology. 2013;120(8):1619-1631. doi:10.1016/j.ophtha.2013.01.005.
  12. Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2015(4):CD010015. doi:10.1002/14651858.cd010015.pub3.
  13. Christen WG, Cook NR, Manson JE, Buring JE, Chasman DI, Lee IM, et al. Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial. JAMA Ophthalmol. 2020;138(12):1280-1289. doi:10.1001/jamaophthalmol.2020.4409.
  14. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009;169(4):335-341. doi:10.1001/archinternmed.2008.574.
  15. Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Arch Clin Exp Ophthalmol. 2013;251(12):2711-2723. doi:10.1007/s00417-013-2376-6.
  16. Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84(4):718-728. doi:10.1016/j.exer.2006.12.010.
  17. Куроедов АВ, Баландина ЕВ, Гапонько ОВ, Диордийчук СВ, Дорофеев ДА, Зубкова ЕЮ, et al. Многоцентровое двойное слепое плацебо-контролируемое сравнительное рандомизированное исследование по изучению эффективности и безопасности лекарственного препарата Ретиналамин у пациентов с «сухой» формой возрастной макулярной дегенерации (RetinGero). Часть 1. Дизайн и исходные данные пациентов. Клиническая офтальмология. 2025;25(4):250-6. doi:10.32364/2311-7729-2025-25-4-4.
  18. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. doi:10.1056/nejmoa054481.
  19. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. doi:10.1056/nejmoa062655.
  20. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908. doi:10.1056/nejmoa1102673.
  21. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. doi:10.1016/j.ophtha.2012.03.053.
  22. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267. doi:10.1016/s0140-6736(13)61501-9.
  23. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548. doi:10.1016/j.ophtha.2012.09.006. Erratum in: Ophthalmology. 2013;120(1):209-210.
  24. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201. doi:10.1016/j.ophtha.2013.08.011.
  25. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/s0140-6736(22)00010-1.
  26. Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141-1152. doi:10.1016/s0140-6736(24)00063-1.
  27. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72-84. doi:10.1016/j.ophtha.2019.04.017.
  28. Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050-1059. doi:10.1016/j.ophtha.2020.11.011.
  29. Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146-152. doi:10.1016/j.ophtha.2014.07.041.
  30. Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020;37(3):1173-1187. doi:10.1007/s12325-020-01236-x.
  31. Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2019;126(5):723-734. doi:10.1016/j.ophtha.2018.11.025.
  32. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123(8):1751-1761. doi:10.1016/j.ophtha.2016.03.045.
  33. Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, et al. Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Ophthalmol. 2021;139(6):610-619. doi:10.1001/jamaophthalmol.2021.0640.
  34. Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, et al. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(5):542-547. doi:10.1001/jamaophthalmol.2021.0221.
  35. Chan CK, Lalezary M, Abraham P, Elman M, Beaulieu WT, Lin SG, et al. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial. Ophthalmol Retina. 2022;6(6):484-494. doi:10.1016/j.oret.2022.01.019.
  36. Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020;127(2):186-195. doi:10.1016/j.ophtha.2019.07.011.
  37. Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434-1448. doi:10.1016/s0140-6736(23)01520-9.
  38. Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021;128(4):576-586. doi:10.1016/j.ophtha.2020.08.027.
  39. Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402(10411):1449-1458. doi:10.1016/s0140-6736(23)01583-0.
  40. Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2024;8(1):9-20. doi:10.1177/24741264231220224. Erratum in: J Vitreoretin Dis. 2024;8(3):363. doi:10.1177/24741264241238212.
  41. Apellis Pharmaceuticals, Inc. SYFOVRE (pegcetacoplan injection): prescribing information [Internet]. DailyMed; 2025 Jul [cited 2026 Oct 18]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4434e61-9ec9-4e0e-bd60-45aaa0a87e64
  42. US Food and Drug Administration. Drug Trials Snapshots: IZERVAY [Internet]. [cited 2026 Oct 18]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-izervay
  43. European Medicines Agency. Syfovre: refusal of the marketing authorisation [Internet]. 2024 [cited 2026 Oct 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre
  44. Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, et al. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol. 2018;136(6):666-677. doi:10.1001/jamaophthalmol.2018.1544.
  45. Rosenfeld PJ, Dugel PU, Holz FG, Heier JS, Pearlman JA, Novack RL, et al. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial. Ophthalmology. 2018;125(10):1556-1567. doi:10.1016/j.ophtha.2018.03.059. Erratum in: Ophthalmology. 2019;126(3):471-472. doi:10.1016/j.ophtha.2018.12.022.
  46. Keenan TDL, Agrón E, Keane PA, Domalpally A, Chew EY, Age-Related Eye Disease Study Research Group, et al. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. Ophthalmology. 2025;132(1):14-29. doi:10.1016/j.ophtha.2024.07.014.